智通财经APP获悉，创新药概念股集体走低，截至发稿，翰森制药(03692)跌6.69%，报31.54港元；和黄医药(00013)跌4.81%，报17.8港元；信达生物(01801)跌4.05%，报75.75港元；中生制药(01177)跌3.4%，报4.83港元。
消息面上，中东冲突引发的能源通胀正从预期演变为现实压力，全球主要发达经济体央行密集释放加息信号。国海证券在风险提示中指出，若全球及国内宏观货币政策节奏不及预期，将直接影响医药板块的估值水平与投融资环境。创新药、CXO 等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。
值得注意的是，2026年美国临床肿瘤学会（ASCO）年会将于5月29日至6月2日在美国芝加哥举行。本届ASCO共63项研究入选LBA（最新突破性摘要），其中12家企业的13项研究来自中国，创历史新高；同时，94项中国研究入选口头汇报，数量近三年快速增长。上海证券指出，中国药企在国际平台彰显实力，中国创新药全球话语权逐年提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.